118 related articles for article (PubMed ID: 9633886)
1. Aprotinin complements heparin bonding in an in vitro model of cardiopulmonary bypass.
Bannan S; Martin PG
Br J Haematol; 1998 Jun; 101(3):455-61. PubMed ID: 9633886
[TBL] [Abstract][Full Text] [Related]
2. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
[TBL] [Abstract][Full Text] [Related]
3. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
[TBL] [Abstract][Full Text] [Related]
4. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
[TBL] [Abstract][Full Text] [Related]
5. Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy.
Wendel HP; Schulze HJ; Heller W; Hoffmeister HM
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4):388-92. PubMed ID: 10468249
[TBL] [Abstract][Full Text] [Related]
6. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
Dietrich W
J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
[TBL] [Abstract][Full Text] [Related]
7. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
8. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
[TBL] [Abstract][Full Text] [Related]
9. Experimental studies on three types of heparin-coated cardiopulmonary bypass circuits.
Baba T; Morisita K; Sakata J; Ito T; Hachiro Y; Kazui T; Abe A; Komatu S
Artif Organs; 1997 Jul; 21(7):779-81. PubMed ID: 9212957
[TBL] [Abstract][Full Text] [Related]
10. Aprotinin in perspective.
Westaby S
Ann Thorac Surg; 1993 Apr; 55(4):1033-41. PubMed ID: 7682054
[TBL] [Abstract][Full Text] [Related]
11. The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation.
Korn RL; Fisher CA; Livingston ER; Stenach N; Fishman SJ; Jeevanadam V; Addonizio VP
J Thorac Cardiovasc Surg; 1996 May; 111(5):1073-84. PubMed ID: 8622305
[TBL] [Abstract][Full Text] [Related]
12. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
[TBL] [Abstract][Full Text] [Related]
13. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
14. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
Wen Z; Zhu F; He X; Xiong S; He S
Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
[TBL] [Abstract][Full Text] [Related]
15. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage.
Mössinger H; Dietrich W
Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S45-50; discussion S50-1, S74-6. PubMed ID: 9647138
[TBL] [Abstract][Full Text] [Related]
16. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
Wendel HP; Heller W; Gallimore MJ
Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
[TBL] [Abstract][Full Text] [Related]
17. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT.
Ganter MT; Dalbert S; Graves K; Klaghofer R; Zollinger A; Hofer CK
Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133
[TBL] [Abstract][Full Text] [Related]
18. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
19. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
Najman DM; Walenga JM; Fareed J; Pifarré R
Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854
[TBL] [Abstract][Full Text] [Related]
20. Low heparinization with heparin-bonded bypass circuits: is it a safe strategy?
Bannan S; Danby A; Cowan D; Ashraf S; Martin PG
Ann Thorac Surg; 1997 Mar; 63(3):663-8. PubMed ID: 9066381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
